Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1900 1
1901 1
1981 1
1982 1
1983 3
1984 2
1985 1
1987 1
1992 1
1995 2
1996 2
1997 2
1998 1
2001 1
2003 3
2004 2
2009 2
2010 1
2012 3
2013 5
2014 3
2016 1
2017 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Free PMC article. Clinical Trial.
Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
Stanworth SJ, Dyer C, Choo L, Bakrania L, Copplestone A, Llewelyn C, Norfolk D, Powter G, Littlewood T, Wood EM, Murphy MF; TOPPS Study Group. Stanworth SJ, et al. Among authors: copplestone a. Transfus Med Rev. 2010 Jul;24(3):163-71. doi: 10.1016/j.tmrv.2009.11.002. Transfus Med Rev. 2010. PMID: 20656185 Review.
A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, Norfolk D, Copplestone A, Smith N, Kerr P, Jones G, Raj K, Westerman DA, Szer J, Jackson N, Bardy PG, Plews D, Lyons S, Bielby L, Wood EM, Murphy MF; TOPPS Investigators. Stanworth SJ, et al. Among authors: copplestone a. N Engl J Med. 2013 May 9;368(19):1771-80. doi: 10.1056/NEJMoa1212772. N Engl J Med. 2013. PMID: 23656642 Free article. Clinical Trial.
Cytarabine in pre-leukaemia.
Mufti GT, Oscier DG, Hamblin TJ, Copplestone A, Abidi SM. Mufti GT, et al. Among authors: copplestone a. Lancet. 1984 May 26;1(8387):1187. doi: 10.1016/s0140-6736(84)91438-7. Lancet. 1984. PMID: 6144915 No abstract available.
Management of blood loss in Jehovah's Witnesses.
Busuttil D, Copplestone A. Busuttil D, et al. Among authors: copplestone a. BMJ. 1995 Oct 28;311(7013):1115-6. doi: 10.1136/bmj.311.7013.1115. BMJ. 1995. PMID: 7580701 Free PMC article. No abstract available.
The implementation of NICE guidance on venous thromboembolism risk assessment and prophylaxis: a before-after observational study to assess the impact on patient safety across four hospitals in England.
Bateman AG, Sheaff R, Child S, Boiko O, Ukoumunne OC, Nokes T, Copplestone A, Gericke CA. Bateman AG, et al. Among authors: copplestone a. BMC Health Serv Res. 2013 Jun 4;13:203. doi: 10.1186/1472-6963-13-203. BMC Health Serv Res. 2013. PMID: 23734903 Free PMC article.
38 results